Telomerase Reverse Transcriptase Expression is Increased Early in the Barrett's Metaplasia, Dysplasia, Adenocarcinoma Sequence

Journal of Gastrointestinal Surgery

Volumn 4, Issue 2, 2000, Pages 135-142

  Lord, Reginald V N ^c   Salonga, Dennis ^b   Danenberg, Kathleen D ^b   Peters, Jeffrey H ^c   DeMeester, Tom R ^c   Park, Ji Min ^b   Johanson, Jan ^c   Skinner, Kristin A ^c   Chandrasoma, Para ^a   DeMeester, Steven R ^c   Bremner, Cedric G ^c   Tsai, Pefer I ^c   Danenberg, Peter V ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NONE

Author keywords

Barrett's esophagus; Esophageal adenocarcinoma; Esophageal neoplasms; hTERT; hTRT; Telomerase; Telomerase reverse transcriptase; Telomere

Indexed keywords

DNA BINDING PROTEIN; MESSENGER RNA; PRIMER DNA; RNA; TELOMERASE; TELOMERASE RNA;

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; BIOSYNTHESIS; CELL TRANSFORMATION; ENZYMOLOGY; ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; DNA PRIMERS; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TELOMERASE;

EID: 0034146097     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(00)80049-9     Document Type: Article

References (73)

1. Chow WH, Finkle WD, McLaughlm JK, et al. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995, 274:474-477
2. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-831.
3. Zhuang Z, Vortmeyer AO, Mark EJ, et al. Barrett's esophagus: Metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res 1996;56:1961-1964.
4. Barrett MT, Sanchez CA, Prevo LJ, et al Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22: 106-109.
5. Cameron AJ, Zinsmeister AR, Ballard DJ, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990;99:918-922.
6. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am J Gastroenterol 1994;89:670-680.
7. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998,83:2049-2053.
8. Lord RV, Law MG, Ward RL, et al. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998;13:356-362.
9. Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's oesophagus: Education, enthusiasm, or epidemiology? Lancet 1997;350:933.
10. Watson A, Reed PI, Caygill CP, et al. Changing incidence of columnar-lined (Barrett's) oesophagus (CLO) in the UK. Gastroenterology 1999;116:A351.
11. DeMeester TR. Surgical treatment of dysplasia and adenocarcinoma. Gastroenterol Clin North Am 1997:26:669-684.
12. Blackburn EH, Gall JG. A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. J Mol Biol 1978;120:33-53.
13. de Lange T, Shiue L, Myers RM, et al. Structure and variability of human chromosome ends. Mol Cell Biol 1990,10: 518-527.
14. Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988;85:6622-6626.
15. Olovnikov AM. Principle of marginotomy in template synthesis of polynucleotides. Doklady Akademii Nauk SSSR 1971;201:1496-1499.
16. Watson JD. Origin of concatemeric T7 DNA. Nature New Biol 1972;239:197-201.
17. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990,345:458-460.
18. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of lifespan by introduction of telomerase into normal human cells. Science 1998;279:349-352.
19. Allsopp RC, Vazin H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992;89:10114-10118.
20. Colgm LM, Reddel RR. Telomere maintenance mechanisms and cellular immortalization. Curr Opin Genet Dev 1999, 9:97-103
21. Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999;96:701-712.
22. Fossel M. Telomerase and the aging cell: Implications for human health. JAMA 1998;279:1732-1735.
23. Vaziri H, Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998;8:279-282.
24. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-2015.
25. Bryan TM, Englezou A, Dalla-Pozza L, et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Med 1995;3:1271-1274.
26. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997,277:955-959.
27. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90:785-795.
28. Kilian A, Bowrell DD, Abud HE, et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex spicing patterns in different cell types. Hum Mol Genet 1997,6:2011-2019.
29. Harrington L, Zhou W, McPhail T, et al. Human telomerase contains evulutionarily conserved catalytic and structural subunits. Genes Dev 1997;11:3109-3115.
30. Holt SF, Shay JW. Role of telomerase in cellular proliferation and cancer. J Cell Physiol 1999;180:10-18.
31. Urquidi V, Tarin D, Goodison S. Telomerase in cancer: Clinical applications. Ann Med 1998;30:419-430.
32. Engelhardt M, Drullinsky P, Guillem J, Moore MA. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer Clin Cancer Res 1997;3:1931-1941.
33. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997;278:1054-1059.
34. Vasef MA, Ross JS, Cohen MB. Telomerase activity in human solid tumors. Diagnostic utility and clinical applications. Am J Clin Pathol 1999;112:S68-S75.
35. Morales CP, Lee EL, Shay JW. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 1998;83: 652-659.
36. Weinrich SL, Pruzan R, Ma L, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 1997,17:498-502.
37. Counter CM, Meyerson M, Eaton EN, et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998;16:1217-1222.
38. Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998;18:65-68.
39. Ulaner GA, Hu JF, Vu TH, et al. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 1998;58:4168-4172.
40. Avilion AA, Piatyszek MA, Gupta J, et al. Human telomerase RNA and telomerase activity in immortal cell lines and tumor tissues. Cancer Res 1996,56:645-650.
41. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
42. Held CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR Genome Res 1996;6:986-994.
43. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996;6:995-1001.
44. Jiang XR, Jimenez G, Chang E, et al. Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 1999;21:111-114.
45. Morales CP, Holt SE, Ouellette M, et al. Absence of cancer-associated changes in human fibroblasts unmortalized with telomerase. Nat Genet 1999;21:115-118.
46. Kiyonu T, Foster SA, Koop JL, et al. Both Rb/p161NK4a in-activation and telomerase activity are required ro immortalize human epithelial cells. Nature 1998;396:84-88.
47. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-538.
48. Klump B, Hsieh C, Holzmann K, et al. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998;115:1381-1386.
49. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-1873.
50. Hayashi K, Metzger R, Salonga D, et al. High frequency of simultaneous loss of p16 and p16beta gene expression in squamous cell carcinoma of the esophagus but not in adenocarcinoma of the esophagus of stomach. Oncogene 1997;15:1481-1488.
51. Schneider PM, Casson AG, Levin B, et al. Mutations of p53 in Barrett's esophagus and Barrett's cancer: A prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996;111: 323-331.
52. Ireland AP, Shibata D, Chandrasoma P, et al. The clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg 2000;231:179-187.
53. Casson AG, Tammemagi M, Eskandarian S, et al. p53 alterations in oesophageal cancer: Association with clinicopathological features, risk factors, and survival. Mol Pathol 1998; 51:71-79.
54. Ireland AP, Clark GW, DeMeester TR. Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg 1997, 225:17-30
55. Gleeson CM, Sloan JM, McGuigan JA, et al. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995;55:3406-3411.
56. Gonzalez MV, Artimez ML, Rodrigo L, et al. Mutation analysis of the p53, APC, and p 16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 1997; 50:212-717.
57. Hamelin R, Flejou JF, Muzeau F, et al. TP53 gene mutations and p53 protein immunoreactivity in malignant and pre-malignant Barrett's esophagus. Gastroenterology 1994;107: 1012-1018.
58. Neshat K, Sanchez, CA, Galipeau PC, et al. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994;106:1589-1595.
59. Boynton RF, Huang Y, Blount PL, et al. Frequent loss of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res 1991;51:5766-5769.
60. Platyszek MA, Kim NW, Weinrich SL, et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 1995;17:1-15.
61. Tsai PI, Danenberg KD. Lord V, et al. Increase in retinoic acid receptor-α expression and decrease in retinoic acid receptor-γ expression in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. Proc Annu Meet Am Assoc Cancer Res 1999;40:A2053.
62. Lord RV, Danenberg K, Peters JH, et al. Increased COX-2 and iNOS expression and decreased COX-1 expression in Barrett's esophagus and Barrett's associated adenocarcinomas. Proc Annu Meet Am Assoc Cancer Res 1999; 40:A2109.
63. Lord RV, O'Grady R, Sheehan C, et al. K-rus codon 12 mutations in Barrett's oesophagus and Barrett's associated adenocarcinomas. J Gastroenterol Hepatol 1999 (in press).
64. Park JM, Danenberg K, Lord RV, et al. Induction of vascular endothelial growth factor and basic fibroblast growth factor expression in Barrett's esophagus and Barrett's-associated adenocarcinomas. Proc Am Assoc Cancer Res 1999;40:A1519.
65. Shay JW, Gazdar AF. Telomerase in the early detection of cancer. J Clin Pathol 1997;50:106-109.
66. Kolquist KA, Ellisen LW, Counter CM, et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998;19:182-186.
67. Vazin H, Dragowska W, Allsopp RC, et al. Evidence for a mitotic clock in human humatopoietic stem cells: Loss of telomeric DNA with age. Proc Nad Acad Sci USA 1994;91:9857-9860.
68. Bodnar AG, Kim NW, Effros RB, Chiu CP. Mechanism of telomerase induction during T cell activation. Exp Cell Res 1996;228:58-64.
69. Asai A, Kiyozuka Y, Yoshida R, et al. Telomere length, telommerase activity and telomerase RNA expression in human esophageal cancer cells: Correlation with cell proliferation, differentiation and chemosensitivity to anticancer drugs. Anticancer Res 1998;18:1465-1472.
70. Koyanagi K, Ozawa S, Ando N, et al. Clinical significance of telomerase activity in the non-cancerous epithelial region of oesophageal squamous cell carcinoma. Br J Surg 1999;86: 674-679.
71. Ikeguchi M, Kaibara N. Telomerase activity in esophageal squamous cell carcinoma and in normal esophageal epithelium adjacent to carcinoma. Nippon Rinsho 1998;56:1176-1180.
72. Hiyama T, Yokozaki H, Kitadai Y, et al. Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis. Virchows Arch 1999;434:483-487.
73. Yajima T, Yagihashi A, Kameshima H, et al. Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the TaqMan fluorogenic detection system. Clin Chem 1998;44:2441-2445.